6Schiller JH. New directions for ZD1839 in the treatment of solid tumors[ J ]. Semin Oncol, 2003,30 (Suppl 1): 49 - 55. 被引量：1
7Lorusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease- related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors[J ]. Clin Cancer Res, 2003,9(6): 2040 - 2048. 被引量：1
二级参考文献18
1Fukuoka M,Yano S,Giaccone G, et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2003 Jun 15,21(12):2237-2246.Epub 2003 May 14. 被引量：1
2LoRusso PM,Herbst RS,Rischin D, et al.Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors[J].Clin Cancer Res,2003 Jun,9(6):2040-2048. 被引量：1
3Schiller JH.New directions for ZD1839 in the treatment of solid tumors[J].Semin Oncol,2003 Feb,30(1 Suppl 1):49-55. 被引量：1
4Baselga J,Rischin D,Ranson M.Calvert HPhase I safety,pharmacokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002 Nov 1,20(21):4292-4302. 被引量：1
5Lorusso PM.Phase I studies of ZD1839 in patients with eommon solid tumors[J].Semin Oncol,2003 Feb,30(1 Suppl 1):21-29. 被引量：1
6Okamoto I,Fujii K,Matsumoto M, et al.Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer[J].Lung Cancer,2003 Jun,40(3):339-342. 被引量：1
7Sirotnak FM.Studies with ZD1839 in preclinical models[J].Semin Oncol,2003 Feb,30(1 Suppl 1):12-20. 被引量：1
